Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Platelet function testing

Paul Harrison, PhD
Section Editor
Lawrence LK Leung, MD
Deputy Editor
Jennifer S Tirnauer, MD


Platelets play a key role in both hemostasis and thrombosis. Accordingly, not only is accurate measurement of platelet function critical for identifying patients with platelet dysfunction or hyperfunction, but it also is becoming increasingly important for the monitoring of modern antiplatelet therapy.

The history of platelet function testing began over 100 years ago when platelets were first identified as distinct circulating cells, rather than fragments, and it was found that they were vital for both hemostasis and thrombosis [1]. Despite these early observations, for the majority of the 20th century the only means of assessing platelet function were a small number of fairly unreliable tests (eg, manual platelet count, inspection of the peripheral blood smear, bleeding time).

A major problem concerning the testing of platelet function is the difficulty in simulating hemostasis in vitro. In addition, platelets are sensitive to manipulation, and are prone to artifactual in vitro activation. Early attempts to simulate hemostasis in vitro included methods in which platelets were counted before and after exposure to foreign surfaces (eg, glass columns) or thrombus formation was monitored within closed plastic tube loops. Many of these early tests remained as research tools because of their technical difficulty, and were thus restricted to specialized centers.

The ability to test platelet function in the routine laboratory improved with the introduction of platelet aggregometry [2]. Remarkably, further advances in laboratory platelet analysis have lagged behind both the functional and molecular analysis of the coagulation/fibrinolytic system. The table (table 1) illustrates the small number of tests that were available up to the late 1980s. The availability of newer and more reliable platelet function analyzers, flow cytometry, and molecular biological techniques is changing our approach to platelet function analysis. Another table (table 2) lists a number of relatively new platelet function tests that are currently available.

This topic review will present a brief history of platelet function testing, and will review major advances in the analysis of platelet function.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Mar 3, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Bizzozero J. On a new blood particle and its role in thrombosis and blood coagulation. Virchows Arch B Cell Pathol Incl Mol Pathol 1982; 90:261.
  2. BORN GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194:927.
  3. BRECHER G, SCHNEIDERMAN M, CRONKITE EP. The reproducibility and constancy of the platelet count. Am J Clin Pathol 1953; 23:15.
  4. England JM, Rowan RM, Bins M, et al. Recommended methods for the visual determination of white cell and platelet counts. WHO LAB 1988; 3:1.
  5. Harrison P, Horton A, Grant D, et al. Immunoplatelet counting: a proposed new reference procedure. Br J Haematol 2000; 108:228.
  6. Bowles KM, Bloxham DM, Perry DJ, Baglin TP. Discrepancy between impedance and immunofluorescence platelet counting has implications for clinical decision making in patients with idiopathic thrombocytopenia purpura. Br J Haematol 2006; 134:320.
  7. Ault K. Platelet Counting: Is there room for improvement. Laboratory Hematology 1996; 2:265.
  8. Gmür J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991; 338:1223.
  9. Ancliff PJ, Machin SJ. Trigger factors for prophylactic platelet transfusion. Blood Rev 1998; 12:234.
  10. Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. Br J Haematol 1998; 101:609.
  11. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia. N Eng J Med 1997; 337:1870.
  12. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.
  13. Stanworth SJ, Denton K, Monteath J, Patton WN. Automated counting of platelets on the Bayer ADVIA 120 analyser. Clin Lab Haematol 1999; 21:113.
  14. Briggs C, Harrison P, Grant D, et al. New quantitative parameters on a recently introduced automated blood cell counter--the XE 2100. Clin Lab Haematol 2000; 22:345.
  15. Davis B, Bigelow N. Indirect immunoplatelet counting by flow cytometry as a reference method for platelet count calibration. Laboratory Hematology 1999; 5:15.
  16. Kunz D, Kunz WS, Scott CS, Gressner AM. Automated CD61 immunoplatelet analysis of thrombocytopenic samples. Br J Haematol 2001; 112:584.
  17. Harrison P, Ault KA, Chapman S, et al. An interlaboratory study of a candidate reference method for platelet counting. Am J Clin Pathol 2001; 115:448.
  18. Ault KA, Mitchell J, Knowles C, Van Hove L. Implementation of the immunological platelet count on a hematology analyser, the Abbot CELL-DYN 4000. Laboratory Hematology 1997; 3:125.
  19. Kickler TS, Rothe M, Blosser L, et al. Improving platelet transfusion therapy using the ImmunoPLT method on the CELL-DYN 4000. Laboratory Hematology 1998; 4:80.
  20. Arroyo JL, García-Marcos MA, López A, et al. Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. Transfusion 2001; 41:1212.
  21. Segal HC, Briggs C, Kunka S, et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol 2005; 128:520.
  22. Harrison P, Segal H, Briggs C, et al. Impact of immunological platelet counting (by the platelet/RBC ratio) on haematological practice. Cytometry B Clin Cytom 2005; 67:1.
  23. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998; 135:S170.
  24. Carville DG, Schleckser PA, Guyer KE, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998; 30:171.
  25. Campbell J, Ridgway H, Carville D. Plateletworks: a novel point of care platelet function screen. Mol Diagn Ther 2008; 12:253.
  26. Hayward CP, Pai M, Liu Y, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7:676.
  27. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7:1029.
  28. Jennings I, Woods TA, Kitchen S, Walker ID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008; 61:950.
  29. Quiroga T, Goycoolea M, Matus V, et al. Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays. Br J Haematol 2009; 147:729.
  30. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997; 96:3860.
  31. Born GV, Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 1967; 215:1027.
  32. Frojmovic MM, Milton JG, Duchastel A. Microscopic measurements of platelet aggregation reveal a low ADP-dependent process distinct from turbidometrically measured aggregation. J Lab Clin Med 1983; 101:964.
  33. Thompson NT, Scrutton MC, Wallis RB. Particle volume changes associated with light transmittance changes in the platelet aggregometer: dependence upon aggregating agent and effectiveness of stimulus. Thromb Res 1986; 41:615.
  34. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3:135.
  35. Mackie IJ, Jones R, Machin SJ. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J Clin Pathol 1984; 37:874.
  36. Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost 1999; 82:1307.
  37. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18:199.
  38. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:849.
  39. Solis RT, Wright CB, Gibbs MB. Electronic particle size measurements of platelet aggregates formed in vitro. J Appl Physiol 1975; 38:739.
  40. Ozaki Y, Satoh K, Yatomi Y, et al. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218:284.
  41. Yamamoto T, Egawa Y, Shirasawa Y, et al. A laser light scattering in situ system for counting aggregates in blood platelet aggregation. Meas Sci Technol 1995; 6:174.
  42. Eto K, Takeshita S, Ochiai M, et al. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res 1998; 40:223.
  43. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330:956.
  44. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998; 97:5.
  45. Cox D. Methods for monitoring platelet function. Am Heart J 1998; 135:S160.
  46. Frelinger AL, Hillman RS. Novel methods for assessing platelet function. Am Heart J 1998; 136:S184.
  47. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99:620.
  48. Kereiakes DJ, Mueller M, Howard W, et al. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombolysis 1999; 7:265.
  49. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95:860.
  50. Duke WW. The relation of blood platelets to hemorrhagic disease. JAMA 1910; 55:1185.
  51. Ivy AC, Shapiro PF, Melnick P. The bleeding time in Jaundice. Surgery, Gynecol Obstet 1935; 60:781.
  52. Mielke CH Jr, Kaneshiro MM, Maher IA, et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34:204.
  53. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16:1.
  54. Yardumian DA, Mackie IJ, Machin SJ. Laboratory investigation of platelet function: a review of methodology. J Clin Pathol 1986; 39:701.
  55. Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1988; 41:1322.
  56. Proceedings on the symposium: Novel techniques involving platelet activity in flow. Florence, Italy. Thromb Res 1997; 92:S23.
  57. Dickinson KJ, Troxler M, Homer-Vanniasinkam S. The surgical application of point-of-care haemostasis and platelet function testing. Br J Surg 2008; 95:1317.
  58. Görög P, Ahmed A. Haemostatometer: a new in vitro technique for assessing haemostatic activity of blood. Thromb Res 1984; 34:341.
  59. Li CK, Hoffmann TJ, Hsieh PY, et al. Xylum CSA: automated system for assessing hemostasis in simulated vascular flow. Clin Chem 1997; 43:1788.
  60. Conan K, Li N, Hoffmann TJ, et al. The Xylum Clot Signature Analyser: A dynamic flow sytstem that simulates vascular injury. Thromb Res 1998; 92:S677.
  61. Gorog DA, Kovacs IB. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. Thromb Haemost 1995; 73:514.
  62. Kratzer MA, Born GV. Simulation of primary hemostasis in vitro. Hemostasis 1985; 5:357.
  63. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995; 21 Suppl 2:106.
  64. Kundu SK, Heilmann EJ, Sio R, et al. Characterization of an In vitro Platelet Function Analyser, PFA-100TM. Clin Appl Thromb hemost 1996; 2:241.
  65. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195.
  66. Harrison P, Robinson MS, Mackie IJ, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10:25.
  67. Carcao MD, Blanchette VS, Dean JA, et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998; 101:70.
  68. Francis J, Francis D, Larson L, et al. Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? Platelets 1999; 10:132.
  69. Carcao MD, Blanchette VS, Stephens D, et al. Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100). Br J Haematol 2002; 117:961.
  70. Zupan IP, Sabovic M, Salobir B, et al. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003; 42:746.
  71. Zupan IP, Sabovic M, Salobir B, et al. The study of anaemia-related haemostasis impairment in haemodialysis patients by in vitro closure time test. Thromb Haemost 2005; 93:375.
  72. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130:3.
  73. Haubelt H, Anders C, Vogt A, et al. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol 2005; 130:759.
  74. Roschitz B, Thaller S, Koestenberger M, et al. PFA-100 closure times in preoperative screening in 500 pediatric patients. Thromb Haemost 2007; 98:243.
  75. Quiroga T, Goycoolea M, Muñoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004; 2:892.
  76. Fressinaud E, Veyradier A, Sigaud M, et al. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999; 106:777.
  77. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82:35.
  78. Posan E, McBane RD, Grill DE, et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90:483.
  79. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91:1325.
  80. Cattaneo M, Lecchi A, Agati B, et al. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999; 96:213.
  81. Marshall PW, Williams AJ, Dixon RM, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997; 44:151.
  82. Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83:316.
  83. Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost 2001; 86:880.
  84. Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4:312.
  85. Varon D, Dardik R, Shenkman B, et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85:283.
  86. Varon D, Lashevski I, Brenner B, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998; 135:S187.
  87. Kenet G, Lubetsky A, Shenkman B, et al. Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998; 101:255.
  88. Shenkman B, Inbal A, Tamarin I, et al. Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition. Br J Haematol 2003; 120:597.
  89. O'Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long bleeding time in von Willebrand's disease. Blood 1987; 70:1354.
  90. Elwood PC, Beswick A, Pickering J, et al. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study. Br J Haematol 2001; 113:514.
  91. Reverter JC, Béguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98:863.
  92. Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. J Biol Chem 1997; 272:27183.
  93. Hardisty RM, Hutton RA. Platelet aggregation and the availability of platelet factor 3. Br J Haematol 1966; 12:764.
  94. Dargaud Y, Luddington R, Baglin T. Platelet-dependent thrombography: a method for diagnostic laboratories. Br J Haematol 2006; 134:323.
  95. Despotis GJ, Levine V, Filos KS, et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85:1311.
  96. Despotis GJ, Levine V, Saleem R, et al. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999; 354:106.
  97. Coiffic A, Cazes E, Janvier G, et al. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Thromb Res 1999; 95:83.
  98. Trentalange MJ, Walts LF. A comparison of thromboelastogram and template bleeding time in the evaluation of platelet function after aspirin ingestion. J Clin Anesth 1991; 3:377.
  99. Orlikowski CE, Payne AJ, Moodley J, Rocke DA. Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects. Br J Anaesth 1992; 69:159.
  100. Blais N, Pharand C, Lordkipanidzé M, et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102:404.
  101. Carr ME Jr, Zekert SL. Measurement of platelet-mediated force development during plasma clot formation. Am J Med Sci 1991; 302:13.
  102. Carr ME Jr. Measurement of platelet force: the Hemodyne hemostasis analyzer. Clin Lab Manage Rev 1995; 9:312.
  103. Greilich PE, Carr ME Jr, Carr SL, Chang AS. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995; 80:459.
  104. Carr ME Jr, Carr SL, Hantgan RR, Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost 1995; 73:499.
  105. Greilich PE, Carr ME, Zekert SL, Dent RM. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am J Med Sci 1994; 307:15.
  106. Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2:924.
  107. Bowry SK, Prentice CR, Courtney JM. A modification of the Wu and Hoak method for the determination of platelet aggregates and platelet adhesion. Thromb Haemost 1985; 53:381.
  108. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77:1081.
  109. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996; 93:11877.
  110. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87:4925.
  111. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6:342.
  112. Schmitz G, Rothe G, Ruf A, et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79:885.
  113. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31:352.
  114. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33:634.
  115. Grau AJ, Ruf A, Vogt A, et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998; 80:298.
  116. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999; 81:373.
  117. Joseph JE, Donohoe S, Harrison P, et al. Platelet activation and turnover in the primary antiphospholipid syndrome. Lupus 1998; 7:333.
  118. Tschoepe D, Schultheiss HP, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88:37.
  119. Li N, Goodall AH, Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates. Br J Haematol 1997; 99:808.
  120. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95:930.
  121. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102:2678.
  122. Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol 1994; 31:312.
  123. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999; 30:111.
  124. Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 1995; 89:117.
  125. Wall JE, Buijs-Wilts M, Arnold JT, et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 1995; 89:380.
  126. Summerfield GP, Keenan JP, Brodie NJ, Bellingham AJ. Bioluminescent assay of adenine nucleotides: rapid analysis of ATP and ADP in red cells and platelets using the LKB luminometer. Clin Lab Haematol 1981; 3:257.
  127. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995; 23:996.
  128. Dale GL, Friese P, Hynes LA, Burstein SA. Demonstration that thiazole-orange-positive platelets in the dog are less than 24 hours old. Blood 1995; 85:1822.
  129. Robinson MS, Mackie IJ, Khair K, et al. Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol 1998; 100:351.
  130. Balduini CL, Noris P, Spedini P, et al. Relationship between size and thiazole orange fluorescence of platelets in patients undergoing high-dose chemotherapy. Br J Haematol 1999; 106:202.
  131. Matic GB, Chapman ES, Zaiss M, et al. Whole blood analysis of reticulated platelets: improvements of detection and assay stability. Cytometry 1998; 34:229.
  132. Harrison P, Robinson MS, Mackie IJ, Machin SJ. Reticulated platelets. Platelets 1997; 8:379.
  133. Rinder HM, Schuster JE, Rinder CS, et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91:1288.
  134. Briggs C, Kunka S, Hart D, et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004; 126:93.
  135. Harrison P, Goodall AH. "Message in the platelet"--more than just vestigial mRNA! Platelets 2008; 19:395.